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Dr. Blumoff:Dr. Berceli and his colleagues are to be congrat-
ulated for the efforts in addressing the difficult problems associated
with surgical care of patients with forefoot osteomyelitis and
associated soft tissue cellulites.
In this study preoperative extent of disease was evaluated by a
combination of physical examination and plain film x-rays. Patients
with extensive proximal tenosynovitis and hindfoot osteomyelitis
were excluded. Study patients were then assigned to one of three
treatment arms—closed, staged or open—based on intraoperative
assessment of disease extent and tissue viability. In this closely
monitored study group, results of amputation followed by planned
staged secondary closure approached those of the primary closure
group while maintaining a distinct advantage in terms of healing
and amputation rates over the open group. Healing of minor
amputations, however, was surprisingly not influenced by presence
or absence of diabetes, pedal pulse status, prior revascularization or
in some cases level of amputation.
Your study raises a few pertinent questions. Did you evaluate
the influence on healing rates of persistent smoking, nutritional
status, absolute lymphocyte count, MRI findings or end-stage
renal disease in the various treatment arms?
Do you have an explanation for the apparently improved
healing rates of diabetics compared to nondiabetics in the open
group?
Lastly, and most thought provoking, is that when all groups
were followed out to 36 months, the early salutary results in the
closed and staged groups were lost with all groups having approx-
imately 35% overall amputation rate. Why? Did revascularization
fail? Did osteomyelitis recur? Or did new pressure ulcers develop at
sites of previous minor amputation? Given these identical rates of
late limb loss as well as the overall poor survival in these patients,
what are your current recommendations regarding patients requir-
ing open amputation?
I’d like to thank the authors again and the society for allowing
me to review this manuscript.
Dr. Berceli: In terms of other predictors of outcome, we did
look at smoking as one of the variables. Unfortunately, a majority
of patients were smokers, maybe secondary to the VA patient
population, so we were unable to make any useful conclusion in
this group. Similarly, while we looked at elevated creatinine as a
variable, the prevalence of dialysis-dependent end-stage renal dis-
ease was not large enough to comment on this group either. In
terms of the use of MRI, we use this sporadically and have not
really identified its clear role in our management algorithm. Lastly,
although it may have been interesting to evaluate leukocyte count
as a predictor for healing, this was not part of our analysis.
I think you are right and the outcomes for diabetics versus
nondiabetics provides an interesting comparison. Amongst the
important components that affect healing in these patients is a
neuropathic foot and clearly that is the diabetic subpopulation.
Further investigation into this issue is warranted. In terms of our
treatment algorithm has changed, we are more aggressive in terms
of staging people to obtain the benefits of that treatment approach.
With the high risk of limb loss despite early healing, our practice is
to identify those patients who would be good prosthetic ambula-
tors and offer major amputation, instead of repeated attempts at
foot salvage, if they are interested.
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